Cargando…

TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers

The TMPRSS2-ERG gene fusion is found in approximately half of all prostate cancers. The functional and prognostic significance of TMPRSS2-ERG is, however, not fully understood. Based on a historical watchful waiting cohort, an association between TMPRSS2-ERG, evaluated as positive immune staining, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hägglöf, Christina, Hammarsten, Peter, Strömvall, Kerstin, Egevad, Lars, Josefsson, Andreas, Stattin, Pär, Granfors, Torvald, Bergh, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914792/ https://www.ncbi.nlm.nih.gov/pubmed/24505269 http://dx.doi.org/10.1371/journal.pone.0086824

Ejemplares similares

High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting
por: Hammarsten, Peter, et al.
Publicado: (2016)

Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome
por: Hammarsten, Peter, et al.
Publicado: (2019)

Stromal PDGFRβ Expression in Prostate Tumors and Non-Malignant Prostate Tissue Predicts Prostate Cancer Survival
por: Hägglöf, Christina, et al.
Publicado: (2010)

High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting
por: Nilsson, Maria, et al.
Publicado: (2015)

Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression
por: Hammarsten, Peter, et al.
Publicado: (2012)

Fatty Acid Amide Hydrolase in Prostate Cancer: Association with Disease Severity and Outcome, CB(1) Receptor Expression and Regulation by IL-4
por: Thors, Lina, et al.
Publicado: (2010)

Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions
por: Lundholm, Marie, et al.
Publicado: (2015)

ErbB2 Receptor Immunoreactivity in Prostate Cancer: Relationship to the Androgen Receptor, Disease Severity at Diagnosis and Disease Outcome
por: Hammarsten, Peter, et al.
Publicado: (2014)

Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017)

Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status
por: Dudka, Ilona, et al.
Publicado: (2020)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
por: Deplus, Rachel, et al.
Publicado: (2016)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2021)

The Stroma—A Key Regulator in Prostate Function and Malignancy
por: Hägglöf, Christina, et al.
Publicado: (2012)

Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis
por: Strömvall, Kerstin, et al.
Publicado: (2017)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer
por: Hansen, Ailin Falkmo, et al.
Publicado: (2016)

PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells
por: Zhou, Feng, et al.
Publicado: (2019)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway
por: Afshari, Afsoon, et al.
Publicado: (2021)

A TMPRSS2‐ERG gene signature predicts prognosis of patients with prostate adenocarcinoma
por: Zhou, Emily, et al.
Publicado: (2020)

TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence
por: Fang, Lei, et al.
Publicado: (2022)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases
por: Brandi, Franziska, et al.
Publicado: (2018)

Temporal changes in cause‐specific death in men with localised prostate cancer treated with radical prostatectomy: a population‐based, nationwide study
por: Thomsen, Frederik B., et al.
Publicado: (2021)

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling
por: Brase, Jan C, et al.
Publicado: (2011)

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer
por: Urbinati, Giorgia, et al.
Publicado: (2015)

TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer
por: Krstanoski, Zoran, et al.
Publicado: (2016)

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2023)

Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth
por: Strömvall, Kerstin, et al.
Publicado: (2017)

Adaptive (TINT) Changes in the Tumor Bearing Organ Are Related to Prostate Tumor Size and Aggressiveness
por: Adamo, Hanibal Hani, et al.
Publicado: (2015)

Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations
por: Pascal, Laura E, et al.
Publicado: (2016)

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer
por: Kluth, Martina, et al.
Publicado: (2018)

Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status
por: Mancarella, Caterina, et al.
Publicado: (2017)

Reduced number of CD169(+) macrophages in pre‐metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients
por: Strömvall, Kerstin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_co9jc58gjcdr8o9vl6k2rkmf4r